ALBUQUERQUE, S. E. C.; AGUIAR, S. M. S.; http://lattes.cnpq.br/2981891670452813; http://lattes.cnpq.br/8993319592931140; ALBUQUERQUE, Sara Elisabete Conceição de.; AGUIAR, Sara Maria Santiago de.
Abstract:
Graves' disease is the most common etiology of hyperthyroidism, and
because it has severe cardiovascular consequences, it is necessary to institute the
most cost-effective therapy. The objective of this study is to highlight the profile of
patients treated with GD at HUAC and to evaluate the cost-benefit of therapies
employed to treat this condition considering this profile. The present study was
based on the review of hospitalization records performed at HUAC between 2012
and 2018, under ICD-10 E05 and variants. 58.4% of the patients had low education,
35.3% lived in rural areas, 35.3% had no access to basic sanitation; 63.6% had
irregular use of medications, 71.4% had loss of follow-up, 44.7% readmitted and
58.8% achieved remission, of which 70.6% after radioiodine. The total cost of the
treatments of 8 selected patients was R$ 59,856.73, which would early treat with
radioiodine 100% of new cases of DG in CG each year. Comparing the cost-benefit
ratio between the two therapies, it is noticeable that if definitive radioiodine therapy
were employed early, the expense would be considerably lower. Considering the
socioeconomic profile of most of the population served by the SUS, early radioiodine
therapy should be considered in such patients because it is free and easily adhered
to.